Contents

Search


fosaprepitant (Emend)

Indications: - chemotherapy-induced nausea/vomiting Dosage: 150 mg weekly IV infusion [2] Mechanism of action: - prodrug of aprepitant Notes: Manufacturer: Merk

Related

aprepitant (Emend)

General

anti-emetic

Database Correlations

PUBCHEM correlations

References

  1. Prescriber's Letter 16(2): 2009 New Drugs Approved by the FDA in 2008 Detail-Document#: 250213 (subscription needed) http://www.prescribersletter.com
  2. Yang Q, Zou X, Xie YL et al Fosaprepitant Weekly vs Every 3 Weeks for the Prevention of Concurrent Chemoradiotherapy-Induced Nausea and Vomiting. A Pilot Randomized Clinical Trial. JAMA Netw Open. 2023;6(7):e2326127. July 27 PMID: 37498596 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2807658